靶向HER2的抗体药物偶联物治疗晚期非小细胞肺癌研究进展  

Research progress of antibody drug conjugations targeting HER2 in the treatment of advanced non-small cell lung cancer

作　　者：高蓉 赵红[1] GAO Rong;ZHAO Hong(Department of Medical Oncology,Af filiated Hospital of Yan'an University,Yan an,Shaanri 716oo0,China)

机构地区：[1]延安大学附属医院肿瘤内科,陕西延安716000

出　　处：《社区医学杂志》2025年第1期32-36,共5页Journal Of Community Medicine

摘　　要：从抗体药物偶联(ADC)的作用机制、ADC在人表皮生长因子受体2(HER2)改变的晚期非小细胞肺癌(NSCLC)治疗中的临床前研究及临床研究等几方面回顾文献并总结靶向HER2改变的ADC药物治疗晚期NSCLC的最新治疗进展,有望为靶向HER2改变ADC在晚期NSCLC的临床应用提供参考。利用中国知网中文数据库,以“抗体药物偶联物”“非小细胞肺癌”“HER2”为关键词,检索2019-01-01-2024-04-01相关文献。利用PubMed英文数据库,以“antibody drug conjugates”“non-small cell lung cancer”“HER2”为关键词,检索2019-01-01-2024-04-01相关文献。纳入标准:(1)ADC药物在NSCLC治疗中的作用机制;(2)ADC在HER2改变NSCLC治疗中的基础研究;(3)ADC在HER2改变NSCLC治疗中的临床研究。剔除标准:(1)重复发表的文献;(2)年份较远的综述类文献;(3)质量较差、语言结构混乱的文献。符合要求纳入分析共31篇文献。结果表明,ADC有望成为HER2改变NSCLC的主要研究方向和下一个突破,且与HER2过表达NSCLC患者相比,ADC疗效在HER2突变型NSCLC患者中疗效更高,其未来的发展是有希望的。Reviewed the literature on the mechanism of antibody drug conjugates(ADC),the preclinical studies and clinical studies of ADC in the treatment of advanced non-small cell lung cancer(NSCLC)with human epidermal growth factor receptor 2(HER2)modification,and summarize the latest progress in the treatment of advanced NSCLC with ADC drugs targeting HER2 modification.It was expected to provide a reference for the clinical application of HER2-targeting ADCs in advanced NSCLC.Using the Chinese database of CNKI,literature related to 2019-01-01 to 2024-04-01 was retrieved with the keywords"antibody drug conjugate","non-small cell lung cancer"and"HER2".References from 2019-01-01 to 2024-04-01 were retrieved using PubMed English database using"antibody drug conjugates","non-small cell lung cancer"and"HER2"as keywords.Inclusion criteria:(1)Mechanism of action of ADC drugs in NSCLC treatment;(2)Basic research of ADC in HER2 changing the treatment of NSCLC;(3)Clinical study of ADC in HER2-modified NSCLC treatment.Exclusion criteria:(1)Duplicate publications;(2)Review literature of relatively distant years;(3)Literature with poor quality and chaotic language structure.A total of 31 literatures were included in the analysis.The results show that ADC is expected to become the main research direction and the next breakthrough in HER2-changed NSCLC.In addition,compared with patients with HER2-overexpressed NSCLC,ADC has a higher efficacy in patients with HER2-mutant NSCLC,and its future development is promising.

关 键 词：抗体药物偶联物 人表皮生长因子受体2 非小细胞肺癌 综述文献 

分 类 号：R734.2[医药卫生—肿瘤]